CAP focuses on later-stage private and public companies in the healthcare and life sciences sectors, specifically those developing innovative drug discovery tools, devices, and services for human healthcare. They have made 13 investments, including Labcyte, QuesCom, and Sapphire Digital, and have had 6 exits, with notable companies such as Labcyte and Acorda Therapeutics. CAP specializes in early and late venture, growth capital, and PIPE investments, and typically invests in rounds with 4-5 participants.